Balanced Pharma Inc.
Less Painful, Faster-Acting Dental Injections
On a Mission to Improve Patient Comfort
Invest in a Better Dental Anesthetic
$4.00
Price Per Share
$996
Minimum Investment
Non-Voting Common Stock
Securities Offered
On a Mission to Improve Patient Comfort
Invest in a Better Dental Anesthetic
Dr. Scott Keadle, a dentist for over 30 years, experienced firsthand the limitations of current dental anesthetic drugs and their inability to provide a fast-acting, reliable, and painless injection.
He wanted a better anesthetic for his patients: Less injection pain, less waiting time, and more reliability.
Dr. Keadle invented patented technology to enable pH-balanced versions of the most common local anesthetics, using a standard syringe and protocol. He then presented the opportunity to a group of dentists who invested over $1 million to help found Balanced Pharma Incorporated (BPI).
Now he leads a team of industry experts who are committed to bringing the first-ever pH-balanced dental anesthetic to market.
On a Mission to Improve Patient Comfort
Invest in a Better Dental Anesthetic
Dr. Scott Keadle, a dentist for over 30 years, experienced firsthand the limitations of current dental anesthetic drugs and their inability to provide a fast-acting, reliable, and painless injection.
He wanted a better anesthetic for his patients: Less injection pain, less waiting time, and more reliability.
Dr. Keadle invented patented technology to enable pH-balanced versions of the most common local anesthetics, using a standard syringe and protocol. He then presented the opportunity to a group of dentists who invested over $1 million to help found Balanced Pharma Incorporated (BPI).
Now he leads a team of industry experts who are committed to bringing the first-ever pH-balanced dental anesthetic to market.
Company Overview
Dental Injections are Unnecessarily Painful and Slow-Acting
- Dentists report that current dental injections have a 20% average failure rate
- 58% of patients believe the injection is the worst part of the dental experience
- 86% of patients want a less-painful dental injection
- 90% of dentists want an improved dental anesthetic
Dental Injections are Unnecessarily Painful and Slow-Acting
- Dentists report that current dental injections have a 20% average failure rate
- 58% of patients believe the injection is the worst part of the dental experience
- 86% of patients want a less-painful dental injection
- 90% of dentists want an improved dental anesthetic
Each Year, Patients Suffer Nearly 2 Billion Dental Injections
These injections are stressful for both patients and dentists, and for good reason:
- The acid preservative in local anesthetic drugs causes pain during injectionand a delayed anesthetic effect.
- Local anesthetic pH can be 25,000 times more acidic than human tissue.
- For dentists, this means uncomfortable patients, wasted time, and wasted money.
Each Year, Patients Suffer Nearly 2 Billion Dental Injections
These injections are stressful for both patients and dentists, and for good reason:
- The acid preservative in local anesthetic drugs causes pain during injectionand a delayed anesthetic effect.
- Local anesthetic pH can be 25,000 times more acidic than human tissue.
- For dentists, this means uncomfortable patients, wasted time, and wasted money.
Pitch Deck
Products & Services
Introducing Libracaine® Dental
LIDOCAINE HCL 2% / EPINEPHRINE 1:100,000 / SODIUM BICARBONATE 0.7%
The First and Only pH-Balanced Dental Anesthetic in the Convenience of a Standard Dental Cartridge
- Less painful, faster-acting, more reliable
- Patented cartridge technology3
- 505(b)(2) abbreviated FDA regulatory pathway
- A pH-balanced version of the most often-used anesthetic4 in dentistry:
- Same safety profile, same 24-month shelf life
- No new equipment, no new protocols
- Supplied in a standard dental cartridge
Peer Testimonial
"A pH-balanced anesthetic in a standard dental cartridge will be a game changer.."
Jason Goodchild, DMDDr. Goodchild is Vice President of Clinical Affairs at Premier Dental Products and holds academic appointments at the University of Pennsylvania School of Dental Medicine, Rutgers School of Dental Medicine, and Creighton University School of Dentistry. He has authored more than 50 research papers on the subject of dental pain management.
The Team
Committed to Excellence in Patient Comfort
John Scott Keadle
Chairman & CEO
Founder & CEO at Balanced Pharma, 30+ years as a dentist, practice owner & business executive.
John Selig
Board Director
Managing Partner at WaveEdge Capital, 25+ years in life science investment banking and M&A practice.
Mark Sebree
Board Director, Chief Development Officer
35+ years experience establishing and implementing strategy in the pharmaceutical industry.
Deal Terms
$4.00 per share (Minimum: 249 shares)
Raise Target:$25M
All Investors Welcome (All income and wealth levels)
All Investors Welcome (All income and wealth levels)
Fundraising Description
| Securities offered: | 6,250,000 shares of Common Stock
|
|
Common Stock outstanding immediately before the Offering(1) |
20,610,000 |
|
Common Stock outstanding immediately after the Offering, assuming a fully subscribed Offering(2)(3) |
26,860,000 |
Use of Funds
| $5M | $7.5M | $15M | $25M | |
| Gross Proceeds to the Company | $5.00 | $7.50 | $15.00 | $25.00 |
| Estimated offering fees and expenses | $400,000 | $550,000 | $850,000 | $1,252,000 |
| Net Proceeds | $4,600,000 | $6,950,000 | $14,150,000 | $23,748,000 |
| Product Development | $900,000 | $1,300,000 | $1,300,000 | $2,300,000 |
| Product Manufacturing | $1,700,000 | $2,000,000 | $4,000,000 | $7,000,000 |
| Product Marketing & Disease Awareness | $ -- | $500,000 | $3,700,000 | $7,350,000 |
| Fundraising | $1,000,000 | $1,250,000 | $2,750,000 | $3,598,000 |
| Intellectual Property Development | $200,000 | $300,000 | $300,000 | $400,000 |
| General & Administrative | $800,000 | $1,600,000 | $2,100,000 | $3,100,000 |
| Total net use of proceeds | $4,600,000 | $6,950,000 | $14,150,000 | $23,748,000 |
|---|
Risks and Disclosures
Investing in start-up or early developmental companies is very risky and you should be prepared to lose your investment or wait a significant time before realizing any economic benefit from it. Therefore, it’s very important that you consider your immediate and future income needs and invest no more than you can afford to lose.
Securities purchased in a crowdfunding transaction generally cannot be resold for a specific period of time, unless certain conditions are met. We encourage you to thoroughly read all offering documentation and refer to our Investor FAQ’s to ensure you are familiar with the characteristics of the types of securities JUSTLY offers, and the risks associated with them. Please ensure you understand the terms of what you are investing in before investing.
Documents
Offering Circular (1 File)
Offering Circular Supplement (1 File)
Updates
Check back here for the latest news!
FAQs
Making an Investment in Balanced Pharma Inc.
When you complete your investment on JUSTLY, your money will be transferred to an escrow account where an independent escrow agent will watch over your investment until it is accepted by the issuer. Once the Issuer accepts your investment, and certain regulatory procedures are completed, your money will be transferred from the escrow account to the Issuer in exchange for your securities.
To make an investment, you will need the following information readily available:
- Personal information such as your current address and phone number
- Employment and employer information
- Net worth and income information
- Your accredited investor status
- Social Security Number or passport
- ABA bank routing number and checking account number (typically found on a personal check or bank statement) or debit card information, unless paying via a Wire transfer.
When you complete your investment on JUSTLY, your money will be transferred to an escrow account where an independent escrow agent will watch over your investment until it is accepted by the issuer. Once the Issuer accepts your investment, and certain regulatory procedures are completed, your money will be transferred from the escrow account to the Issuer in exchange for your securities.
To make an investment, you will need the following information readily available:
- Personal information such as your current address and phone number
- Employment and employer information
- Net worth and income information
- Your accredited investor status
- Social Security Number or passport
- ABA bank routing number and checking account number (typically found on a personal check or bank statement) or debit card information, unless paying via a Wire transfer.
After My Investment
Currently there is no market or liquidity for these securities. Right now the Issuer does not plan to list these securities on a national exchange or another secondary market. At some point the Issuer may choose to do so, but until then you should plan to hold your investment for a significant period of time before a “liquidation event” occurs. A “liquidation event” is when the Issuer either lists their securities on an exchange, is acquired, or goes bankrupt.
You can view your portfolio of investments within your upon initiating your investment. If the offering closes successfully and you are accepted as a shareholder/investor, you may receive periodic updates from the Company.
Currently there is no market or liquidity for these securities. Right now the Issuer does not plan to list these securities on a national exchange or another secondary market. At some point the Issuer may choose to do so, but until then you should plan to hold your investment for a significant period of time before a “liquidation event” occurs. A “liquidation event” is when the Issuer either lists their securities on an exchange, is acquired, or goes bankrupt.
You can return to JUSTLY at any time to view your portfolio of investments and obtain a summary statement. If invested under Regulation CF you may also receive periodic updates from the company about their business, in addition to monthly account statements.
Comments